STOCK TITAN
  1. Home
  2. News
  3. VERV

Verve Therapeutics, Inc. - VERV STOCK NEWS

Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.

Verve Therapeutics, Inc. (VERV) is a clinical-stage biotechnology pioneer developing single-course gene editing treatments for cardiovascular disease. This news hub provides investors and healthcare professionals with essential updates on therapeutic advancements, clinical trial progress, and strategic developments.

Access comprehensive coverage of VERV's innovative pipeline including PCSK9, ANGPTL3, and LPA gene editing programs. Our curated news collection features regulatory milestones, partnership announcements, and scientific breakthroughs in base editing technology.

Stay informed about Verve's cutting-edge approach to permanently modifying cholesterol-related genes through precise liver-targeted therapies. The page aggregates official press releases, trial result analyses, and expert commentary while maintaining strict financial compliance standards.

Bookmark this page for real-time updates on Verve Therapeutics' mission to transform cardiovascular care through durable genetic medicines. Check regularly for new developments in this rapidly evolving sector of precision biotechnology.

News

Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Rhea-AI Summary
Verve Therapeutics CEO to participate in fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference. The company is pioneering a new approach to cardiovascular disease with single-course gene editing medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences
-
News

Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Verve Therapeutics (VERV) to Present at J.P. Morgan Healthcare Conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
News

Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement

Rhea-AI Summary
Verve Therapeutics, Inc. (Nasdaq: VERV) has successfully closed an underwritten public offering of 14,375,000 shares of its common stock at a public offering price of $10.00 per share, resulting in total gross proceeds of approximately $143.8 million. Additionally, the company announced the closing of a private placement of 2,296,317 shares of its common stock to Eli Lilly and Company, at a price per share equal to the public offering price, totaling approximately $23.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
offering
News

Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement

Rhea-AI Summary
Verve Therapeutics, Inc. (Nasdaq: VERV) announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, for total gross proceeds of $125.0 million. In addition, Verve has agreed to sell 2,296,317 shares of its common stock to Eli Lilly and Company in a private placement, resulting in aggregate gross proceeds of approximately $148.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
offering
-
News

Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Rhea-AI Summary
Verve Therapeutics, Inc. (Nasdaq: VERV) has commenced an underwritten public offering of shares of its common stock and intends to sell up to $35 million of its common stock to Eli Lilly and Company in a private placement. The company also plans to grant the underwriters a 30-day option to purchase additional shares. Jefferies, Guggenheim Securities, William Blair, BMO Capital Markets, and RBC Capital Markets are acting as joint book-running managers for the public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
offering
-
News

Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

Rhea-AI Summary
Verve Therapeutics, Inc.: First human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101 revealed LDL-C reductions of up to 55% and blood PCSK9 protein reductions of up to 84%. The safety profile supports continued development of VERVE-101, with enrollment ongoing in the 0.45 mg/kg and 0.6 mg/kg cohorts and plans to initiate an expansion cohort in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Verve Therapeutics, Inc. has made significant progress in developing single-course gene editing medicines for cardiovascular disease, with FDA clearing its Investigational New Drug Application for VERVE-101 in HeFH patients. Verve also announced an expanded collaboration with Eli Lilly and Company and the acquisition of product rights to Verve's PCSK9 and ANGPTL3 programs. The company reported $485.2 million in cash, cash equivalents, and marketable securities, ensuring cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.83%
Tags
earnings
-
News

Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3

Rhea-AI Summary
Verve Therapeutics has announced that Eli Lilly and Company (Lilly) has acquired certain product rights to Verve's cardiovascular gene editing programs from Beam Therapeutics. The product candidates are designed to lower low-density lipoprotein cholesterol in patients with or at risk for cardiovascular disease. Lilly now holds the product rights previously held by Beam, including the right to opt-in to share development expenses and to jointly commercialize the products in the United States. Verve retains control of development and commercialization outside the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.95%
Tags
none
-
News

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

Rhea-AI Summary
Verve Therapeutics receives FDA clearance to conduct clinical trial for cardiovascular disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
News

Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023

Rhea-AI Summary
Verve Therapeutics to present interim data from its heart-1 Phase 1b clinical trial of VERVE-101 at AHA Scientific Sessions 2023. VERVE-101 aims to reduce LDL cholesterol. Investor event to be held on November 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.75%
Tags
conferences clinical trial
Stock VERV logo
Verve Therapeutics, Inc.

Nasdaq:VERV

VERV Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

VERV Stock Data

400.47M
84.22M
5.04%
90.12%
16.74%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON